Nectar Life Sciences, a NYC-based innovative and comprehensive allergy care platform, raised $8m in seed funding.
The round was led by Juxtapose and Obvious Ventures.
The company intends to use the funds to continue developing proprietary and personalized allergy solutions ahead of the nationwide launch of Nectar in the coming months.
Led by Founder and CEO Kenneth Chahine, Ph.D., Nectar will be the consumer-facing brand of Nectar Life Sciences, an allergy-focused healthcare holding company.
The Nectar platform will leverage data and clinical research to offer personalized allergy care aimed at treating the root cause of allergies and providing long-lasting relief. Its differentiated model will provide consumers with long-needed convenience, flowing between virtual care and physical clinics for comprehensive allergy care targeting environmental, pet, and food allergies, eczema and asthma.
Its vertically integrated operations will power telehealth experiences and a licensed compounding pharmacy to create personalized, innovative, and proprietary treatments for consumers.
FinSMEs
17/03/2022